Related Experiment Video
Updated: May 19, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Normal tissue protection for improving radiotherapy: Where are the Gaps?
Pataje G S Prasanna1, Helen B Stone, Rosemary S Wong
1Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
Translational Cancer Research
|August 7, 2012
Summary
Radiation therapy can control tumors, but normal tissue injury remains a challenge. New research explores radioprotectors and mitigators to improve cancer treatment outcomes by protecting healthy tissues.
Area of Science:
- Oncology
- Radiation Biology
- Pharmacology
Background:
- Radiation therapy is a cornerstone of cancer treatment, but normal tissue toxicity limits its efficacy.
- Technological advancements improve radiation dose conformity, yet normal tissues are still exposed.
- Understanding normal tissue injury mechanisms and developing radioprotectors are crucial for enhancing radiation therapy outcomes.
Purpose of the Study:
- To review current knowledge on normal tissue injury from radiation therapy.
- To explore the development and application of novel radioprotectors and mitigators.
- To discuss strategies for improving radiation therapy by minimizing side effects and enhancing tumor control.
Main Methods:
- Review of recent scientific literature on radiation biology, normal tissue injury, and radioprotective agents.
- Analysis of mechanisms of cellular damage, repair, and response to radiation.
- Discussion of drug development concepts for radiation therapy.
Main Results:
- Normal tissue injury is a significant limitation in radiation therapy, varying by organ and radiation dose.
- Emerging research focuses on biomarkers and countermeasures for normal tissue protection.
- Radioprotectors and mitigators show promise but require careful consideration of their impact on tumor response.
Conclusions:
- Developing effective radioprotectors and mitigators necessitates a multi-faceted approach, considering site-specific needs.
- Advances in understanding tissue biology and injury mechanisms are vital for progress.
- Future strategies should integrate normal tissue protection into clinical cancer care to improve patient outcomes.
